

46
179AstraZeneca Pharmaceuticals I.P.
Docket No. PHM.70293/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Aiyar, J., *et al.*
Filed: December 10, 1998
Application No. 09/209,125

For: HUMAN BRAIN-DERIVED TISSUE-SPECIFIC POTASSIUM CHANNEL

Via FACSIMILE transmission to: 703-305-3704
Assistant Commissioner for Patents
Washington, DC 20231

Attention: Group Art Unit: 1646
Examiner: Nirmal S. Basi


ATTORNEY REPRESENTATION

Sir:

I, Kenneth F. Mitchell, Intellectual Property Attorney, AstraZeneca Pharmaceuticals I.P., a Business Unit of ZENECA Inc., hereby represent that I am authorized to act in a representative capacity on behalf of Applicants in all matters involving the above-identified Application. This change of Attorney for Applicants, according to the provisions of 37 CFR 1.34(a) and MPEP 402, is necessitated due to a change of composition of the corporate patent staff of AstraZeneca Pharmaceuticals LP.

Therefore, Applicants hereby revoke all previous Powers of Attorney and respectfully request that those practitioners associated with Customer Number 22466 be recognized as the Attorneys of Record for Applicants, with power to inspect, prosecute and transact all other business in the Patent and Trademark Office in connection with the above-identified Application.

Respectfully submitted,
AstraZeneca Pharmaceuticals I.P.



Kenneth F. Mitchell, Ph.D.
Attorney for Applicants
Reg. No. 42,007
Telephone: 302/886-7466

Dated: April 6, 2000